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Abstract
Alzheimer’s disease (AD) is characterized by brain accumulation of the neurotoxic amyloid-b peptide (Ab) and by loss of
cholinergic neurons and nicotinic acetylcholine receptors (nAChRs). Recent evidence indicates that memory loss and
cognitive decline in AD correlate better with the amount of soluble Ab than with the extent of amyloid plaque deposits in
affected brains. Inhibition of nAChRs by soluble Ab40 is suggested to contribute to early cholinergic dysfunction in AD.
Using phage display screening, we have previously identified a heptapeptide, termed IQ, homologous to most nAChR
subtypes, binding with nanomolar affinity to soluble Ab40 and blocking Ab-induced inhibition of carbamylcholine-induced
currents in PC12 cells expressing a7 nAChRs. Using alanine scanning mutagenesis and whole-cell current recording, we have
now defined the amino acids in IQ essential for reversal of Ab40 inhibition of carbamylcholine-induced responses in PC12
cells, mediated by a7 subtypes and other endogenously expressed nAChRs. We further investigated the effects of soluble
Ab, IQ and analogues of IQ on a3b4 nAChRs recombinantly expressed in HEK293 cells. Results show that nanomolar
concentrations of soluble Ab40 potently inhibit the function of a3b4 nAChRs, and that subsequent addition of IQ or its
analogues does not reverse this effect. However, co-application of IQ makes the inhibition of a3b4 nAChRs by Ab40
reversible. These findings indicate that Ab40 inhibits different subtypes of nAChRs by interacting with specific receptor
domains homologous to the IQ peptide, suggesting that IQ may be a lead for novel drugs to block the inhibition of
cholinergic function in AD.
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Introduction
Alzheimer’s disease (AD) is the most common age-related
neurodegenerative disorder and the seventh leading cause of death
in the United States [1]. Currently, no effective treatment is
available to slow down or stop deterioration of nerve cells in AD.
This irreversible disease appears to be initiated by synapse failure,
resulting in impairment of cognitive and other cerebral functions
[2]. A large body of evidence indicates that the primary agent of
neurodegeneration in AD is a 39–43 amino acid residues long
peptide known as amyloid-b (Ab). The majority of secreted Ab is
40 amino acids long (Ab40), while the longer, 42-amino acid
species (Ab42) has a high propensity to nucleate and drive the
formation of soluble aggregates (e.g., oligomers, protofibrils) and
insoluble amyloid fibrils [3,4,5]. Substantial evidence indicates that
soluble Ab oligomers are the proximal neurotoxins responsible for
synapse dysfunction in AD (for reviews, see [2,6,7]. However, the
mechanisms linking Ab40 to synapse dysfunction and neuronal
loss remain to be fully elucidated.
A prominent feature of AD pathology is the loss of cholinergic
neurons and nicotinic acetylcholine receptors (nAChRs) through-
out the brain [8,9]. With nearly 30 subtypes of brain nAChRs
having been described, the three most abundant nAChR subtypes
in the mammalian brain are composed of a7, a4b2, and a3b4
subunits [10], expressed in major brain areas including cortex and
hippocampus [11]. Although the direct binding of Ab to a7
receptors has been questioned [12], high-affinity association of
Ab42 with a7 and a4b2 nAChRs has been observed in amyloid
plaques and in neurons of AD patients [13,14,15,16]. There is also
considerable evidence that Ab affects the function of nAChRs (for
reviews, see [17,18]). Nanomolar concentrations of Ab42 or Ab40
have been reported to inhibit both human and rat homomeric a7
receptors [19,20,21,22,23,24]. Moreover, Ab has been shown to
exert subtype-specific actions, activating non-a7 nAChRs in rat
basal forebrain neurons [25] and inhibiting non-a7 nAChR
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subtypes (a4b2, a2b2, a4a5b2) in rodent hippocampal slices [26].
In studies employing heterologously expressed human nAChRs,
Ab has been shown to inhibit a7 and a4b2 subtype function
without affecting a3b4 nAChRs [23]. Those effects, however, are
still somewhat controversial, as other reports show that picomolar
concentrations of Ab have no effect [23] or even activate whole-
cell current responses of a7 nAChRs ([27,28,29,30]; for a review,
see [31]).
Using phage-display screening of a peptide library, we
previously reported that soluble Ab binds with nanomolar affinity
to a heptapeptide with aminoacid sequence IQTTWSR, hence-
forth denoted IQ, which is homologous to an amino acid sequence
located at the nicotine and acetylcholine (ACh) binding pocket in
most subtypes of human nAChRs [24]. Nanomolar concentrations
of IQ block Ab-induced inhibition of carbamylcholine-induced
currents in neuronal-differentiated PC12 cells expressing a7
nAChRs, suggesting that inhibition of nAChRs by Ab results
from its binding to the nicotine/ACh binding domain in the
receptor. Our previous results further indicated that Ab interacts
with several nAChR subunits homologous to IQ, such as a
subunits [24]. Crystallographic studies and alignment of nAChR
sequences reveal that the location of the ligand binding site is
highly conserved in nAChRs, but the actual ligand binding
residues may vary, creating specificities for different ligands [32].
Here, we have used a combination of alanine scanning
mutagenesis and rapid kinetic whole-cell current recording
[33,34,35] to define the amino acid residues in IQ that are
essential for alleviating blockade of the inhibition of a7 nAChRs
by Ab40. In addition, we examined the effects of soluble Ab40, IQ
and IQ peptide analogues on a3b4 nAChRs, which are present in
human brain but exhibit low homology to a7 in terms of amino
acid sequences at the nicotine/ACh binding site. Results show that
nanomolar concentrations of soluble Ab40 inhibit a3b4 nAChRs.
In contrast with our previous observations on a7 nAChRs [24], IQ
and its analogues do not block Ab40 inhibition of a3b4 nAChRs.
However, simultaneous exposure to IQ and Ab40 makes the
inhibition of a3b4 nAChRs by Ab40 reversible. These results
suggests that Ab binds to distinct binding sites on different
nAChRs subtypes and point to the region homologous to IQ in
nAChRs as a relevant target for Ab40 neurotoxicity in AD.
Results
Amino acid residues of IQ involved in blocking inhibition
of a7 and other endogenously expressed nAChRs by
Ab40
In order to identify key amino acid residues of the IQ peptide
involved in blockade of Ab-induced inhibition of nAChRs, whole-
cell recordings of nAChR currents were carried out in neuronal-
differentiated PC12 cells. RT-PCR analysis revealed that such
cells express a3, a5, a7, b2 and b4 nAChR subunits, and
measurements in the presence of methyllycaconitine (MLA)
indicated that, on day 2 following induction to neuronal
differentiation, a7 receptors contributed about 50% of cholinergic
receptor-mediated whole cell currents [36].
We have previously shown that soluble Ab40 (200 nM) caused a
marked (,60%) inhibition of nAChR currents and that addition
of 500 nM IQ completely blocked this effect. Control measure-
ments showed that addition of IQ alone (up to 500 nM) did not
elicit any current in differentiated PC12 cells and (up to 750 nM)
did not interfere with currents evoked by carbamylcholine (CCh)
[24]. However, at higher concentrations (.1 mM) IQ inhibited
nAChR-mediated whole cell currents (ICCh) and induced cell
death (data not shown), indicating a relatively narrow concentra-
tion range in which IQ could be safely used to prevent nAChR
inhibition by Ab40 in the absence of cell toxicity.
We have now investigated a series of IQ analogues for their
abilities to block Ab-induced inhibition of nAChRs in the absence
of cell toxicity. A number of peptides were synthesized
corresponding to a full alanine scan of the IQ heptapeptide or
to truncated tetrapeptides. The impact of those peptides on cell
viability was initially tested by the MTT assay, and none of them
exhibited cytotoxicity at concentrations of 1 or 100 mM in PC12
cells (Fig. S1). Moreover, no toxic effects exerted by these peptides
were observed in HEK cells transfected for a3, b4 receptor
expression (data not shown).
Each of the IQ analogue peptides (at a fixed concentration of
500 nM, based on our previous results with IQ; ref 24) was then
tested for its capacity to alleviate Ab-induced inhibition of
nAChRs in PC12 cells (measured in the presence of 0.2 mM
CCh and 200 nM Ab40 in order to assess maximum inhibition
rates; ref 24). Among the tetrapeptides tested, TTWS best
mimicked the effect of full-length IQ (Fig. 1), completely reversing
Ab40 inhibition of nAChR-mediated whole cell currents (ICCh
9562%), followed by TWSR (ICCh 8464%), IQTT (ICCh
8065%) and QTTW (ICCh 7266%). Representative current
traces are shown in Fig. S2. Alanine scanning of the IQ sequence
showed that replacement of Ile eliminated the capacity to block
Ab-induced inhibition of nAChRs (IleRAla, ICCh 5764%).
Moreover, replacement of Trp or Ser residues by Ala resulted in
significantly reduced abilities to block Ab40 inhibition (TrpRAla,
ICCh 7263%; SerRAla, ICCh 7963%).
Effects of Ab, IQ and IQ analogues on a3b4 nAChRs
Given the abundance of a3b4 receptors in the human brain, we
next investigated the inhibition of a3b4 nAChRs by Ab40 in the
presence of 200 nM Ab40 at effective 0.2 mM CCh concentra-
tion. Co-application of 200 nM Ab40 and 0.2 mM CCh resulted
in approximately 35% inhibition of a3b4 nAChR currents in
transformed HEK cells (Fig. 2). Successive shots of 0.2 mM CCh
on the same cell at 5 min intervals (Fig. 2, white bars, shots 1–6)
had no significant effect in the response to CCh, indicating lack of
receptor desensitization under these conditions. However, appli-
cation of three successive shots of 0.2 mM CCh plus 200 nM
Ab40 (Fig. 2, light grey bars, applications 1–3) reduced the cellular
response to CCh to approximately 60% of the control level.
Subsequent application of three additional shots of 0.2 mM CCh
alone to the same cell did not recover the original response to CCh
(Fig. 2, light grey bars, shots 4–6), indicating that a3b4 nAChRs
remained inhibited even after washout of Ab. In fact, Ab-induced
inhibition of a3b4 nAChRs persisted even after 6 successive shots
of CCh (4 minutes between each shot, comprising approximately
30 minutes for each experiment) following a single initial exposure
to 0.2 mM CCh plus 200 nM Ab40 (Fig. S3).
Irreversible inhibition of a3b4 receptors by Ab was also
observed following three shots of 0.2 mM CCh plus 200 nM
Ab40 and 0.5 mM SQI (a control scrambled peptide that has the
same amino acid composition as IQ but does not bind to Ab),
followed by three shots of 0.2 mM CCh alone (Fig. 2, black bars).
Cells that had been exposed to three shots of 0.2 mM CCh plus
200 nM Ab40 in the presence of 0.5 or 2 mM IQ presented
reduced response to CCh stimulation (,60% and 70% of control
currents, respectively; Fig. 2, grey bars, shots 1–3). Thus, in
contrast with its ability to block inhibition of a7 nAChRs [24], IQ
was not capable of preventing the inhibition of a3b4 nAChRs by
Ab. Interestingly, however, the response of a3b4 receptors to CCh
(Fig. 2, grey bars, shots 4–6) returned to control levels during the
washout period after the co-application of CCh, Ab40 and IQ.
Peptides Reversing nAChR Inhibition by b-amyloid
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This indicates that, in the presence of IQ, the inhibition of a3b4
receptors by Ab40 becomes reversible following Ab40 washout.
As a control, we tested whether IQ, QI (a peptide with a reverse
sequence compared to IQ) or SQI induced activation of a3b4
nAChR currents or had any impact on cellular response to CCh.
Results showed that none of the three peptides by themselves
elicited currents or had any detectable effect on whole-cell current
responses of PC12 cells (Fig. S4), supporting the notion that rescue
of cellular a3b4 nAChR response to CCh by IQ is due to its
interaction with Ab.
Finally, we evaluated the effects of IQ and selected peptide
analogues on the inhibition of a3b4 nAChRs by Ab. To this end,
cells received three shots of each peptide as shown in Fig. 3. For all
cells analyzed (at least 3 cells per experimental condition), currents
measured in the presence of the peptides were compared to those
measured in the presence of CCh alone or CCh+Ab. For each cell,
3 shots (with a 4 minute interval between them) of CCh were
applied to elicit maximum responses, then 3 shots of CCh+Ab to
induce inhibition, followed by 3 shots of CCh+Ab+peptide, and
finally 3 more shots of CCh alone in order to verify the persistence
of inhibition.
In the absence of peptides, inhibition by Ab40 was found to be
persistent when CCh alone was applied after the shots of
CCh+Ab. Interestingly, when shots included CCh+A-
b+IQTTWSR (0.5 or 2 mM), a3b4 nAChR currents were rescued
from inhibition when measured in the presence of CCh alone
(after washout of Ab). We next tested the effects of the TTWS and
TWSR tetrapeptides, which had shown the best protective actions
against Ab-induced inhibition of nAChRs, and IQTTASR, which
lacks the highly conserved Trp residue in the agonist-binding
domain of nAChRs and presented the lowest capacity to alleviate
Figure 2. IQ makes Ab40 inhibition of a3b4 nAChR currents in
transformed HEK cells reversible. HEK cells expressing a3b4
nAChRs received consecutive shots (at 5 min intervals) of 0.2 mM
CCh plus 200 nM Ab, in the absence or presence of IQ (0.5 mM) as
indicated. Shots 1–3 contained 0.2 mM CCh alone (white bars), 0.2 mM
CCh plus 200 nM Ab (light grey bars), 0.2 mM CCh plus 200 nM Ab and
0.5/2 mM IQ (grey bars) or 0.5 mM SQI (black bars), used as an inactive
control. Shots 4–6 contained 0.2 mM CCh alone for evaluation of
reversibility of receptor inhibition. Bars represent mean values 6 S.D. of
at least 3 replicate measurements (normalized by the maximal current
evoked by 0.2 mM CCh) obtained from 4–6 different cells. (***,
p,0.001, in comparison with 0.2 mM CCh plus 200 nM Ab).
doi:10.1371/journal.pone.0067194.g002
Figure 1. IQ and selected analogues reverse Ab40 inhibition of nAChRs in PC12 cells. (A) Current responses (normalized by the maximal
current evoked by 0.2 mM CCh) of neuronal-differentiated PC12 cells exposed for 2 s to 0.2 mM CCh plus 200 nM Ab40 in all experimental
conditions, except for the control measurement with CCh alone, and, as indicated, 500 nM of different IQ analogues. Bars represent means 6 S.D. of
at least 3 replicate measurements performed in 4–6 different cells (**, p,0.01; *** p,0.001 in the comparison with the control current evoked by CCh
alone).
doi:10.1371/journal.pone.0067194.g001
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Ab40 inhibition of a7 currents (Fig. 1). A slight increase in Ab-
induced inhibition was observed in the presence of SQI, which,
however, was not statistically significant.
When tested on a3b4 nAChR-expressing cells, all peptides
tested failed in preventing the inhibition of a3b4 nAChR-
mediated currents by Ab. However, when Ab40 was added to
cells in conjunction with IQ, TTWS or IQTTASR (0.5 mM each),
a3b4 nAChR-mediated currents in response to CCh alone
returned to approximately 100%, 88% and 94%, respectively, of
control levels. On the other hand, TWSR, QI and SQI peptides
Figure 3. Effects of IQ and analogues on Ab40 inhibition of a3b4 nAChRs in transformed HEK cells. (A) HEK cells expressing recombinant
a3b4 nAChRs received 3 consecutive shots (at 4 min intervals) of 0.2 mM CCh plus 200 nM Ab40 in the absence or presence of 0.5 and 2 mM
IQTTWSR. QI and SQI (500 nM) were used as ineffective control peptides. Recovery of current response was evaluated after washout and 3 shots of
CCh alone. (B) HEK cells expressing recombinant a3b4 nAChRs received 3 consecutive shots of 0.2 mM CCh plus 200 nM Ab40 in the absence or
presence of 500 nM TTWS, TWSR or IQTTASR. QI and SQI (500 nM) were used as ineffective control peptides. Recovery of current response was
evaluated after washout and 3 shots of CCh alone. Bars represent mean values 6 S.D. of current responses (normalized by the maximal current
evoked by 0.2 mM CCh) of at least 3 measurements performed in at least 3 different cells. (***, p,0.001).
doi:10.1371/journal.pone.0067194.g003
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were unable to rescue the inhibition of CCh-induced a3b4
nAChR-mediated responses by Ab40 (Fig. 3).
Discussion
We have previously identified an Ab40 ligand, a peptide termed
IQ, that blocks Ab-induced inhibition of nAChRs at nanomolar
concentrations [24]. IQ is homologous to the ligand-binding
domain of nAChRs. The location of the ligand-binding site is
conserved among different pentameric ligand gated ion channel
receptors, but the actual ligand binding residues may vary,
creating specificities for different ligands [32]. Therefore, we
proposed that Ab40 might interact with the ligand-binding
domain of distinct nAChRs subunits, preferentially binding to
those with higher homology to IQ, such as a7. This is consistent
with previous reports of higher affinity interactions between Ab40
and a7 than with a4b2 nAChRs from rat and guinea pig cerebral
cortex and from hippocampal synaptic membranes [13,14].
Neuronal nAChRs are assembled as homomeric or heteromeric
combinations of a (a2–10) and b (b2–4) subunits. The majority of
human CNS nAChRs is of the a4b2 subtype and the remainder is
largely made up of a7 subunit homopentamers and a3b4
heteromers, although several other combinations are also known
[10,23].
Here, we have asked which amino acid residues of IQ are
essential for blockade of Ab40 inhibition of receptor currents in
cells containing a7 or heteromeric nicotinic receptors, and
specifically tested the effects of soluble Ab, IQ and IQ analogues
in cells expressing only the a3b4 nAChR subtype. We used a
whole-cell current-recording approach in combination with the
cell-flow technique [33] to briefly expose differentiated PC12 cells
or HEK cells expressing a3b4 nAChRs to Ab40 and other ligands.
This procedure minimizes receptor desensitization and avoids long
periods of incubation with Ab, assuring preservation of Ab40 in
soluble state during the experiments, as previous described [24].
Co-application of 0.2 mM CCh, 200 nM Ab40 and 500 nM of
different IQ analogues to differentiated PC12 cells showed that,
among the tetrapeptides tested, TTWS was the analogue that best
emulated the protective effect of full-length IQ, completely
preventing Ab-induced inhibition of nAChRs (ICCh 9562%).
Next in terms of effectiveness were TWSR, IQTT and QTTW.
Both TTWS and TWSR contain Trp57, a highly conserved
residue present in the sequences of all nAChRs described so far
[37]. Trp57 has been shown to be important for binding of d-
tubocurarine (a competitive antagonist of nAChRs) to Torpedo
nAChR [38]. Both peptides also contain a Ser residue (Ser58)
present in 1 of the 12 human nAChR subunit sequences and
conservatively replaced by Thr in 5 of the remainder 11
sequences. Ala-scanning of the IQ sequence indicated that the
Trp and Ser residues of IQ are essential for efficacy in preventing
Ab40 inhibition of nicotinic receptors. Ala substitutions also
pointed to the importance of Ile in the IQ sequence. Significantly,
Ile53 (or its highly conserved substitution Leu) is present in 11 of
the 12 human nAChR subunits known to date.
On the other hand, replacement of Gln, Thr or Arg residues by
Ala did not significantly affect the efficacy of IQ analogues (Fig. 1),
despite the fact that mutations in Gln56 (numbering according to
the a7 nAChR sequence) affect the affinities for ACh and nicotine
[39]. Collectively, these results show that Ile, Trp and Ser residues
in the amino acid sequence of IQ (IQTTWSR) are essential to
block Ab40 inhibition of nAChRs. Based on these findings, we
propose that protection by longer peptides (containing 6 amino
acid residues or more) can be explained on the basis of a sequence
motif in which Ile, Trp and Ser residues at positions 1, 5 and 6,
respectively, are conserved (i.e., IxxxWS). A similar model can be
developed for shorter peptides (of 4 amino acid residues or less)
and also for protection against inhibition of a3b4 receptors and
possibly other nicotinic subtypes by Ab40 (Fig. 4). For a7 nicotinic
receptors and other subtypes expressed by PC12 cells, carbox-
yterminal Trp and Ser residues must be conserved to preserve
efficacy of tetrapetides in blocking Ab40 inhibition. On the other
hand, our results show that for a3b4 receptors the Trp residue can
be replaced by a nonpolar (aliphatic or aromatic) amino acid
residue without loss in activity (Fig. 3B). Defining these structural
motifs may prove useful for development of novel IQ analogues
with improved efficacy in protection against Ab40 inhibition of
nAChRs and/or recovery from such inhibition, and as a
molecular backbone for development of non-peptide drugs.
The fact that IQ is homologous to several nAChR subunits [24]
suggests that Ab40 binds to this highly conserved domain in
different nAChRs subtypes. Although direct binding was not tested
in the present study, we assume a similar mechanism of action for
the other tested peptides. In order to test this hypothesis, we tested
the effects of Ab, IQ and IQ analogues in a cell line expressing a
single subtype of nAChR, the a3b4 subtype, characterized by
large whole-cell current responses and widely used as model for
binding and activity screening on nicotinic receptors
[40,41,42,43,44]. Moreover, this receptor subtype was recently
employed to characterize the mechanism of action of the
Alzheimer drug tacrine [42] and has also been shown to be
involved in disease states such as nicotine-induced seizures and
hypolocomotion in mice [45]. Results showed that 200 nM soluble
Ab40 persistently blocked the response of a3b4 nAChRs to CCh
remaining 60614% of currents induced by CCh alone. To our
knowledge, there is only one other study testing the effects of Ab40
on a3b4 nAChRs [23]. That study showed that Ab failed to elicit
changes in amplitude of ACh-evoked currents mediated by human
a3b4 nAChRs expressed in Xenopus laevis oocytes. It should be
noted, however, that Ab40 was bath applied at a significantly
lower concentration (10 nM) than used in the present study
(200 nM). Moreover, Pym et al. [23] pre-incubated Ab40 with
cells for 3 min, which might lead to aggregation and, consequent-
ly, to a decrease in the concentration of soluble Ab40 species that
directly interact with nAChRs. Although the concentration of
Ab40 in the cerebrospinal fluid of AD patients has been reported
to be between 1 and 10 nM [46], the concentration of Ab40 at
cholinergic synapses is unknown.
In contrast to their effects in cells expressing a7 and heteromeric
nAChRs, IQ and analogues did not block Ab40 inhibition of a3b4
nAChRs expressed in HEK cells, suggesting that IQ binding to
Ab40 is not sufficient to prevent Ab from interacting with and
inhibiting a3b4 receptors. However, addition of IQ made the
inhibition of a3b4 nAChRs by Ab40 reversible, suggesting that IQ
binding to Ab40 modifies its interaction with a3b4 receptors, likely
facilitating Ab40 dissociation and receptor re-activation by the
agonist. Activity screening of IQ analogues indicated that only
TTWS and IQTTASR were able to mimic IQ and make Ab40
inhibition of a3b4 nAChRs reversible, emphasizing the impor-
tance of the TTWS tetrapeptide in Ab40 interaction with
nAChRs. Unexpectedly, the Trp residue (present in all nAChRs)
that is essential in IQ to block Ab40 inhibition of a7 nAChRs was
not necessary to alleviate the effects of Ab40 on a3b4 nAChRs,
suggesting that different amino acid residues or different protein
domains are involved in Ab40 interaction with distinct subtypes of
nAChRs.
Current results support the notion that Ab40 binds with distinct
affinities to and has different effects on various subtypes of
nAChRs [6,27]. Indeed, it has been reported that Ab binds with
Peptides Reversing nAChR Inhibition by b-amyloid
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high affinity (in the picomolar range) to a7 nAChRs in cortical
regions and in the hippocampus in AD, and with about 5,000
times lower affinity to a4b2 nAChRs [13,14]. However, as a
general mechanism, blockade of nAChRs by Ab may also affect, at
concentrations similar to those used in the present study, the
cholinergic control of neurotransmitter release, including glycine,
glutamate, aspartate and GABA [47,48].
Distinct effects of Ab on different subtypes of nAChRs reinforce
the idea that Ab binding to different receptor subtypes may
involve different binding sites, occasionally increasing but more
often blocking agonist response. Moreover, the difference in effects
of IQ and analogues in cells expressing a7 and other heteromeric
receptors versus in cells solely expressing a3b4 nAChRs may be
due to the fact that IQ presents higher homology to the ligand
binding pocket of a7 than of a3b4 nAChRs. In nAChRs, the
ligand-binding site is located at the interface between two subunits
[46,49]. Numerous biochemical studies have shown that the
principal part of the binding site is formed by a-subunit residues
[50,51,52,53], whereas neighboring subunit residues contribute to
form the complementary part of the binding pocket. Thus,
heteropentamers such as a3b4 subtype contain two different
ligand-binding sites with distinct affinities, whereas the homo-
pentameric a7 receptor contains five identical ligand-binding sites
[32]. The most vulnerable neurons in AD seem to be those
expressing high levels of nAChRs, particularly those containing
the a7 subunit [54], and levels of nAChRs as well as some of their
associated proteins decrease in AD [55,56]. An interesting recent
study reported that deletion of the a7 nAChR gene prevents
cognitive deficits and synaptic pathology in a mouse model of
Alzheimer’s disease [57]. Our current results provide novel
information to drive further progress in AD drug design. Drugs
like IQ, capable of disrupting Ab-a7 nAChR interactions, might
alleviate Ab-mediated toxicity and block AD development.
In conclusion, our finding that Ab exerts subtype-specific
inhibitory effects on a7 and a3b4 nAChRs suggests that receptor
subunit composition might account for some of the different
actions reported for Ab40 on neurons in vivo. Furthermore, we
show that the region homologous to IQ in nAChRs is a relevant
target to alleviate blockade of a7 and a3b4 nAChRs by Ab. Our
results identify, for the first time, the amino acid residues probably
involved in binding and inhibition of nAChRs by Ab and may
provide a valuable platform for drug design of novel AD
therapeutics. The potential relevance of our findings to drug
design and development of novel AD treatments is further
underscored by a recent string of disappointing clinical trials on
Ab antibodies (Bapineuzumab and Solanezumab), which have cast
a shadow over anti-Ab immunotherapy strategies [58].
Materials and Methods
Peptide synthesis
Peptides IQ (IQTTWSR), AQTTWSR, IATTWSR,
IQATWSR, IQTAWSR, IQTTASR, IQTTWAR, IQTTWSA,
IQTT, QTTW, TTWS, TWSR and scrambled IQ (SQI;.
TIWQSTR) were synthesized as detailed elsewhere [24].
Figure 4. Suggested conserved amino acid sequence for reversal of a3b4 nAChR inhibition by Ab.
doi:10.1371/journal.pone.0067194.g004
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Cell culture
PC12 cells (ATCC, catalogue # CRL-1721) were cultured and
induced to neuronal differentiation as described [24,36]. Briefly,
PC12 cells were cultured in DMEM (Invitrogen, Life Technolo-
gies, Carlsbad, CA, USA) in the presence of 10% FBS (Cultilab,
Campinas, Sa˜o Paulo, Brazil), 5% horse serum (Invitrogen, Life
Technologies, Carlsbad, CA, USA), streptomycin (100 mg/ml),
penicillin (100 U/ml – Sigma-Aldrich, St. Louis, MO, USA) and
1 mM sodium pyruvate (Invitrogen, Life Technologies, Carlsbad,
CA, USA). N5,29-O-dibutyryl cAMP (dibutyril cAMP) and FGF-2
(45 ng/ml) were added to cultures to induce differentiation into
mature sympathetic neurons expressing increased numbers of
neuronal nAChRs [59]. For differentiation, 2.56105 cells/ml, as
determined by Neubauer chamber counting, were induced to
neuronal differentiation for up to 6 days in DMEM containing
30 ng/ml FGF-2 (Sigma-Aldrich, St. Louis, MO, USA) and
250 mM dibutyril cAMP (Sigma-Aldrich, St. Louis, MO, USA).
Under these conditions, differentiated PC12 cells express a3, a5,
a7, b2 and b4 nicotinic receptor subunits [36]. For evaluation of
cell viability, PC12 cells on day 3 of neuronal differentiation were
exposed for 48 h to different peptides at 1 and 100 mM
concentrations, then washed with PBS and stained with trypan
blue. Five fields were photographed per well and live and dead
cells were counted. Statistical analysis was based on the Student’s
t-test.
Human embryonic kidney cells (HEK293 cells) stably express-
ing rat a3 and b4 nAChR subunits [60] were obtained from Dr.
Yingxian Xiao, Georgetown University. Transfected cells were
cultured in DMEM (Invitrogen, Life Technologies, Carlsbad, CA,
USA) supplemented with 10% FBS, 100 U/ml penicillin G,
100 mg/ml streptomycin and 0.3 mg/ml geneticine (Sigma-
Aldrich, St. Louis, MO, USA) at 37uC and 5% CO2. Cells were
allowed to attach to 35 mm cell culture dishes for 48 h prior to
being used in whole-cell recording experiments.
Whole-cell current recording and rapid application of
ligand solutions (cell flow technique)
PC12 cells following 3–6 days of neuronal differentiation were
cultured at a density of 20–100 cells/mm2 on 35 mm cell culture
dishes. Whole-cell recordings were performed at room tempera-
ture at a transmembrane voltage of 270 mV. The solution in the
recording pipette contained 145 mM KCl, 10 mM NaCl, 2 mM
MgCl2, 1 mM EGTA, 25 mM HEPES, pH 7.4. The bath
solution was composed of 145 mM NaCl, 5.3 mM KCl,
1.8 mM CaCl2, 1.2 mM MgCl2, 10 mM glucose, 25 mM
HEPES, pH 7.4. Further details were previously reported [24].
Using carbamylcholine (CCh), a stable analog of ACh, we have
previously shown that whole-cell current (ICCh) data in neuronal-
differentiated PC12 cells could be well described by a single
binding site model, yielding a Kd of 259658 mM for CCh. A Kd
value of 2 mM has already been determined for a3b4 nAchRs
expressed by HEK cells [61]. According to previous work
published by Niu et al., 1995 and Hess et al. 2000 [62,63], the
equilibrium between open and closed channel forms is defined by
the concentration of the agonist, thereby the closed channel form
reveals higher affinity for the inhibitor as the open channel form
does. Therefore, higher percentages of inhibition by Ab40 are
expected at low CCh (0.2 mM) concentration. Because the density
of receptors in the plasmamembrane (i.e., the total number of
binding sites) differs somewhat from cell to cell, all ICCh values
were normalized to the currents measured in the presence of
0.2 mM CCh [24]. CCh-induced currents were recorded by
whole-cell recording in combination with a rapid kinetic ligand
delivery system, denominated the cell-flow technique, which
provides a time resolution of 10 ms [24,33,34,35]. Briefly, a U-
shaped stainless steel capillary tube (250 mm i.d.) with a circular
porthole of 150 mm in diameter at the base of the U was connected
to pumps on both ends so the solution containing ligand could be
driven into the tube at one end and removed through the other
end at twice the entry flow rate [33]. The porthole was placed
about100 mm away from each cell clamped by the recording
pipette. Upon closing a solenoid valve between the U-tube and the
suction pump by an electric trigger, CCh, Ab40 and/or different
peptides were applied to the cell in a laminar flow. Ab40 and
peptide solutions were mixed prior to co-application with CCh.
Recorded signals were amplified using an Axopatch 200B
amplifier (Molecular Devices, LLC, Sunnyvale, CA, USA) and
filtered at 2 KHz using a 40-pole low-pass Bessel filter. The
filtered signals were digitized using a Digidata 1322A interface,
recorded using the pCLAMP software package (Molecular
Devices) and analyzed using Microcal Origin software (Microcal
Software, Inc., North Hampton, MA, USA). Statistical analysis
was performed by comparing mean values using one-way analysis
of variance (ANOVA) with Bonferroni’s correction.
Correction for receptor desensitization in cell-flow
measurements
The maximum current amplitude is proportional to the density
of open channels. As receptor desensitization may occur while the
ligand solution is equilibrating with the cell surface, observed
current amplitudes are corrected for desensitization using the
equation [33,35]:
I(t)~I1e
{t=t1zI2e
{t=t2zIe, ð1Þ
where I(t) is the maximum current amplitude at time t; I1, I2, Ie are
the maximum current amplitudes for the first, second, and
equilibrium current decay components, respectively; and t1 and t2
are the time constants for the first and second components (fast
and slow receptor desensitization, respectively). Origin software
(Microcal Software, Inc.) was used to estimate the rate of current
decay in the presence of agonist. Equation 1 was fitted to the
decreasing part of the recording and the observed maximum
current amplitude was corrected for receptor desensitization
accordingly [33].
Supporting Information
Figure S1 Cytotoxicity assay selected IQ analogues.
PC12 cells induced to neuronal differentiation were incubated in
the presence of different peptides for 48 hours, washed with PBS
and stained with trypan blue. The percentages of live and dead
cells of five fields per well were counted and compared to those of
control cells incubated in the absence of peptides.
(TIFF)
Figure S2 Current traces of different peptides tested for
reversion of a3b4 nAChR inhibition by Ab40. Current
responses (normalized by the maximal current evoked by 0.2 mM
CCh) of neuronal differentiated PC12 cells exposed for 2 s to
0.2 mM CCh plus 200 nM Ab40 in all experimental conditions,
except for the control measurement with CCh alone, and, as
indicated, 500 nM of different IQ analogues. The here shown
original data are illustrative for mean values 6 S.D. reported in
Fig. 1.
(TIF)
Figure S3 Ab40-induced inhibition of a3b4 nAChR
currents in transformed HEK cells persists after
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washout. Following six consecutive applications of 0.2 mM CCh,
0.2 mM CCh was co-applied once in the presence of 200 nM
Ab40. Following washout of Ab, inhibition persisted in six
consecutive applications of CCh (p,0.005, when compared to
control currents measured prior to Ab administration).
(TIF)
Figure S4 IQ, QI or SQI alone do not instigate nAChR
currents in PC12 cells. The initial whole-cell response induced
by 0.2 mM CCh was normalized to 100% of activity. None of the
peptides (IQ, QI, SQI, tested at 2 mM) induced changes in CCh-
evoked currents nor activated receptor responses in the absence of
agonist. Arrows indicate time points of ligand application.
(TIF)
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